Member Info for Jarv55

Cambridge, 4 September 2019: As previously announced, Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, is unveiling its new revolutionary clinical messaging product, Bleepa, to over 6,000 conference delegates at NHS Expo in Manchester on 4-5 September 2019.

Silly sellers this is a buy and hold how many bought Iqai in the penny area then saw it at 16p?

https://twitter.com/bleepame/status/1154711763557986304?lang=en

Jacksdad the impact on A an E times would be significant market will catch on soon, now is the time to accumulate.

Worth a listen https://www.youtube.com/watch?v=6QfkoebU5QI

welcome on board UKred

https://www.med-technews.com/features/nhs-will-embrace-innovation-if-it-s-the-right-one/

Worth a read https://www.med-technews.com/features/how-a-messaging-service-doubles-up-as-a-medical-device/

Chimaera learn to chart and manage risk.

https://fbkmed.com/texrad-landing-2/

https://www.proactiveinvestors.co.uk/companies/news/903684/feedback-surges-as-texrad-licensee-stonechecker-receives-green-light-from-fda-903684.html

Iqai has fantastic potential as you say but Fdbk is at the bottom of the cycle any sniff of an Nhs deal for Bleepa and this will fly.

Revoy no one said Iqai is rising off the back of Fdbk that is a stupid statement to make. Fdbk supply the Texrad licence to Stonechecker which is suppossed to earn royalty rights for your sales that is the connection. The Texrad lcence is a component of Stonechecker. We are waiting on Fdbk to give us an update.

What the medical experts are saying about TexRAD
"The preliminary TexRAD results were impressive: I was able to identify an invasive breast cancer focus within larger area of pre-operative, non-invasive disease."

- Dr Olga Strukowska, Consultant Radiologist of the Western Sussex Hospitals Trust, Worthing

"TexRAD provides unique tumor information, which in addition to standard morphological assessment, could improve therapeutic assessment in renal cancer treated with tyrosine kinase inhibitors. The preliminary results are encouraging for its use as a predictive biomarker in this clinical context.

Link to the above:-

Https://www.researchgate.net/publication/278964745_TexRad-Feedback_plc_-_Cancer_Management_Imaging_Software
Sussex Innovation Centre website:
Https://www.sinc.co.uk/member-directory/texrad

Vox Podcast from 30:16: Https://audioboom.com/posts/7049194-john-meyer-on-cora-bmn-arcm-and-alan-green-on-pdz-gkp-fdbk-vast

Article about Apps in the health service: Https://www.digitalhealth.net/2018/12/its-not-just-about-instant-messaging-we-need-an-integrated-secure-approach-to-clinical-communication/

Textural Analysis for the Prediction of Cerebrovascular Events Https://www.turing-gateway.cam.ac.uk/presentation/2018-10-17/24558

w-Health Care Solutions India Http://whealthcaresolutions.co.in/texrad-ct-mr-texture-analysis-tool/ added 21st July 2019

FEEDBACK ON TWITTER Https://twitter.com/FBKmed

BLEEPA ON TWITTER Https://twitter.com/BleepaMe

Company Website:- Https://fbkmed.com/

Bleepa: Https://www.bleepa.com/

Latest Interview:August 2019 Https://www.youtube.com/watch?v=6QfkoebU5QI

Previous Interviews: July 2019 Https://www.youtube.com/watch?v=9faprXHq1e0

Apr 2019 Https://www.youtube.com/watch?v=5otg5Pu3XxA

Jan 2019 Https://www.youtube.com/watch?v=t-9ommmMzr4

Dec 2018 Https://www.youtube.com/watch?v=Bof8cklxRHc

Oct 2018 Https://www.youtube.com/watch?v=9lgPGRPWtis

2016 Dr Balaji Ganeshan https://vimeo.com/156252024#t=300s

Vox Podcast from 30:16: Https://audioboom.com/posts/7049194-john-meyer-on-cora-bmn-arcm-and-alan-green-on-pdz-gkp-fdbk-vast

Recent announcements
Sept 2019 Bleepa launched at Manchester Expo
Jul 2019 New medical grade imaging app to be launched at NHS Expo on 4-5 September 2019
Jul 2019 Outcome of strategic review and trading update
Apr 2019 Dr Tom Oakley appointed CEO of Feedback plc and announces plan to complete a full review of the business over the coming weeks, to develop a strategy.
Feb 2019 Feedback Medical appoints radiologist and NHS England Clinical Entrepreneur Fellow, Dr Tom Oakley as CEO
Nov 2018 Feedback Medical Ltd retains international medical devices industry standard certification following independent audit
October 2018 Received a number of new significant orders for TexRAD®, its patented image texture analysis technology, from prestigious university hospitals across Europe.
September 2018 Received an order from its South Korean distributor, Korea Computer ISG, for TexRAD®, for the Samsung Medical Centre in Seoul.
August 2018 First order via GE Healthcare (GEHC) for TexRAD® An order was received from University of Iowa Hospitals and Clinics in Iowa, US.
June 2018 Revised strategy announced.
April 2018 Software licence and distribution agreement with General Electric Healthcare (GEHC) for TexRAD®
April 2018 Signs a new agreement with Royal Papworth Hospital, Cambridgeshire (UK) for the Company's Cadran PACS
From 2015
Seimens (one of the market leaders for scanning machines) are now starting to bundle TexRAD software into their equipment sales.

Major Shareholders
T W G Charlton 83 800 000 Increased to 86 800 000 10th June 2019 120 000 000 2nd Sept
Jonathan David Selby Cranston 30 166 667 Increased to 33 750 000 7th June 2019 42 000 000 30th August
Barnard Nominees 16 666 667 2nd September 2019
University of Sussex 9 400 000
Simon Sturge 12 833 333 19th August 2018
Dr Alastair Riddell 7 000 000 19th August 2018
Mike Hayball 4 520 600 17th August 2018

Deal with Future Processing 15th January 2019

Https://www.future-processing.com/

Herald became the first institution to acquire shares in the recent placing.

Https://www.heralduk.com/

For any newbies DIY some excellent links from Advfn
Number of shares:- 539 949 917

Feedback is a specialist medical imaging technology company.
Potentially a sleeping giant

Products:

Bleepa The future of clinical communication tools and supports clinical teams to work in the way they want to, for the benefit of patients.

Bleepa is a secure instant messaging system that shares clinical grade medical images on personal devices such as phone or tablet.

Bleepa speeds up care for patients by connecting all the members of the clinical team, enabling rapid collective decision making and secure sharing of information.

Https://www.bleepa.com/faq.php

TEXRAD Research

TexRAD Research can quantify texture features in medical images that can reveal more information about the complexity of regions which cannot be gathered by a visual assessment alone.

With applications in Radiomics, TexRAD Research provides radiologists, clinicians and medical researchers with a non-invasive imaging biomarker. With more than 100 academic publications, TexRAD Research demonstrates diagnostic, prognostic and predictive intelligence in scientific research.

Https://fbkmed.com/texrad-landing-2/texrad-research/

TEXRAD a radiomics tool

In the exciting new field of Radiomics, TexRAD uncovers biomarkers in medical images that are typically invisible to the naked eye.
TexRAD’s sophisticated patent-protected algorithm extracts and quantifies texture features in pre-existing medical images. These texture features have been successfully used to demonstrate diagnostic, prognostic and predictive intelligence in scientific research with particular significance in oncology. TexRAD has featured in over 100 academic publications, won numerous awards and is currently used in over 50 prestigious institutions worldwide.

TEXRAD LUNG the first clinical application of TexRAD.
Quantifying texture in PET/CT images, TexRAD Lung can reveal information about the complexity of lung tumours which cannot be gathered by visual assessment alone. TexRAD Lung provides radiologists, clinicians and medical researchers with a non-invasive imaging biomarker. TexRAD Lung is CE marked for clinical use in the EU.

Https://fbkmed.com/texrad-landing-2/texrad-lung/

CADRAN a Picture Archiving and Communication System
Https://fbkmed.com/cadran-landing/

Well done all holders worth looking at Fdbk too after all a part of stonechecker is the Texrad licence.

Jolli expect a few placees who averaged down are taking their profits. Expect an update here soon I assume TO will have been looking into the royalty rights over the weekend.